Apollo Health Ventures

Apollo Health Ventures is a transatlantic early-stage venture capital firm that co-founds and invests in healthcare companies addressing age-related diseases and the biology of aging itself. The firm pursues two parallel activities: an internal venture lab, in which it partners with scientists, research institutes and universities to convert untapped technologies into new companies, and conventional venture investing in externally sourced early-stage companies built on breakthrough science.

The firm focuses on data-driven biotechnology and health tech ventures, backing companies that target validated aging pathways — for example maintaining cellular health and fitness, reducing tissue damage from chronic inflammation, or restoring immune function. Its second fund, closed in December 2021 at $180 million (€157.5 million), supports both venture creation and externally sourced deals. Reported portfolio companies include Aeovian Pharmaceuticals (mTORC1-modulating therapeutics), Auron Therapeutics (oncology), Bloom Science (gut-immune-brain axis), Booster Therapeutics (drug modalities for degenerative diseases), Cleara Biotech (cellular senescence), Focal Biosciences (mechano-biology and cellular reprogramming), Galilei Biosciences (DNA damage repair and metabolic health), HAYA Therapeutics, Ochre Bio, Refoxy Pharma, Samsara Therapeutics (autophagy-enhancing molecules), ThymoFox and additional stealth-mode companies.

Founding story

The firm was co-founded by Nils Regge, a serial entrepreneur and co-founder of TruVenturo who has helped over 30 early-stage startups raise funding, together with Dr. Ole Mensching, a serial entrepreneur and HR expert who previously co-founded and sold CareerTeam, and Dr. Alexandra Bause, who has worked on longevity research since her studies at Harvard. The website dates the firm's track record to 2017, the year in which Nils Regge began focusing on health tech and biotech companies.

Business model

Apollo Health Ventures operates as a venture capital manager, raising funds from institutional and private investors and deploying capital into seed and early-stage healthcare companies. Alongside conventional minority investments, it co-founds companies through its venture lab, acquiring founder shares at nominal value, and leads or participates in follow-on rounds for portfolio companies.

As a venture capital firm, Apollo Health Ventures generates returns from equity stakes in its portfolio companies, including founder shares acquired at nominal value through its venture lab, financed via committed capital from fund investors.

Traction

The firm closed a $180 million second fund in December 2021 and reports a track record dating to 2017. Its portfolio has produced clinical and financing milestones, including Auron Therapeutics' $27 million Series B and FDA clearance in February 2025, FDA Fast Track designation for AUTX-703 in relapsed or refractory acute myelogenous leukemia, and first patient dosing in a Phase 1 trial in May 2025; HAYA Therapeutics' $65 million Series A in May 2025; Therini Bio's additional $39 million Series A in May 2025; and the launch of Booster Therapeutics with $15 million in seed financing in October 2024.

Latest developments

Portfolio news published in 2025 includes Auron Therapeutics dosing its first patient in a Phase 1 trial of AUTX-703 in advanced hematologic malignancies (May 2025), Therini Bio raising an additional $39 million Series A (May 2025), HAYA Therapeutics raising a $65 million Series A (May 2025), and Auron receiving FDA Fast Track designation for AUTX-703 (February 2025) alongside FDA clearance and a $27 million Series B (February 2025).